Categories: Wire Stories

Solasia Announces Launch of Darvias� in Japan

TOKYO–(BUSINESS WIRE)–Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter �Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto).


Contacts

Solasia Pharma K.K.
Toyokazu Ohata, Public Relations and Investor Relations

Tel: +81 3 5843 8046 (TOKYO)

info@solasia.co.jp

Alex

Recent Posts

Minsuzenraku Opens First Hong Kong Location, Bringing Taiwan’s Popular No-Menu Teppanyaki Experience

HONG KONG SAR - Media OutReach Newswire - 22 November 2024 - Minsuzenraku, Taiwan's highly…

1 hour ago

New Directions East Asia 2024: Exploring the Transformative Role of Language Assessment on Education and Society

Bringing together UK and global expertise, the 12th edition of the global language testing and…

3 hours ago

Wine Connection’s Annual Wine Tasting Fair 2024: Discover Your Next Favourite

SINGAPORE - Media OutReach Newswire - 22 November 2024 - Wine enthusiasts in Singapore can…

4 hours ago

Get Wild about the Festive Season with ChristmasVille Furry Monsters Unleash Holiday Fun at Pacific Place and Starstreet Precinct

HONG KONG SAR - Media OutReach Newswire - 22 November 2024 - The spirit of…

4 hours ago

UFC® FIGHT NIGHT MACAU at Galaxy Macau A Thrilling Night of Fights Set for Galaxy Arena on November 23

The Press Conference for the Event Was Held This Afternoon at the Galaxy International Convention…

4 hours ago

HKPC Wins Gold Award in Government PR Category at 20th China Golden Awards for Excellence in Public Relations

HONG KONG SAR - Media OutReach Newswire - 22 November 2024 - The Hong Kong…

4 hours ago